ReviewAdvanced healthcare materials2022
Immunomodulation Strategies for the Successful Regeneration of a Tissue-Engineered Vascular Graft.
Review in Advanced healthcare materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 56 citations in OpenAlex.
- Immuno-resolving nitric oxide-generating stents for coordinated vascular healing.Bioactive materials · 2027Article
- Engineering Multiscale Vasculature: Biological Principles, Design Constraints, and Advanced Biofabrication Strategies for Functional Vascular Networks.Biomimetics (Basel, Switzerland) · 2026Review
- Chronic kidney disease and stromal cell-derived factor 1α peptide-functionalization impact on polycarbonate-bisurea based in situ tissue-engineered vascular graft dynamics.Scientific reports · 2026Article
- Electrospun Carbothane-Based Drug-Enriched Scaffolds for Cardiovascular Devices: Drug Release, Hemocompatibility, Endothelialization, and Immunological Characterization.International journal of molecular sciences · 2026Article
- Reinforced biotubes as readily available and regenerative vascular grafts.Nature communications · 2026Article
- Preparation and in vivo effectiveness evaluation of heparin-loaded PLGA@PCL core-shell fiber small-diameter vascular grafts.PloS one · 2026Article
- Biomaterial-mediated Cell Atlas: an insight from single-cell and spatial transcriptomics.Bioactive materials · 2025Review
- Bioprinted platform for parallelized screening of engineered microtissues in vivo.Cell stem cell · 2025Article
- Improved porosity promotes reendothelialization and smooth muscle remodeling in decellularized tissue-engineered vascular grafts.Materials today. Bio · 2025Article
- Targeting Smad3 Phosphorylation Attenuates Anastomotic Intimal Hyperplasia and Perigraft Fibrosis in Decellularized Tissue-Engineered Vascular Grafts.Biomaterials research · 2025Article
- Quercetin-Loaded Nanoparticle-Modified Decellularized Tissue-Engineered Vascular Graft Regulates Macrophage Polarization and Promotes In Vivo Graft Remodeling.International journal of nanomedicine · 2025Article
- Circumferentially Aligned Electrospun Vascular Grafts Improves Its Vascular Regeneration and Remodeling in vivo.International journal of nanomedicine · 2025Article
- Mesenchymal Stem Cell-Conditioned Media-Loaded Microparticles Enhance Acute Patency in Silk-Based Vascular Grafts.Bioengineering (Basel, Switzerland) · 2024Article
- Biomimetic Approaches in Scaffold-Based Blood Vessel Tissue Engineering.Biomimetics (Basel, Switzerland) · 2024Review
- Endothelial and smooth muscle cell interaction with hydrothermally treated titanium surfaces.In vitro models · 2024Article
- Adaptation process of decellularized vascular grafts as hemodialysis accessRegenerative biomaterials · 2024Article
- A review of the current state in neointimal hyperplasia development following endovascular intervention and minor emphasis on new horizons in immunotherapy.Translational and clinical pharmacology · 2023Review
- The construction of elastin-like polypeptides and their applications in drug delivery system and tissue repair.Journal of nanobiotechnology · 2023Review
- Biodegradable, Self-Reinforcing Vascular Grafts for In Situ Tissue Engineering Approaches.Advanced healthcare materials · 2023Article
- Comparison of the Patency and Regenerative Potential of Biodegradable Vascular Prostheses of Different Polymer Compositions in an Ovine Model.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease leads to the highest morbidity worldwide. There is an urgent need to solve the lack of a viable arterial graft for patients requiring coronary artery bypass surgery. The current gold standard is to use the patient's own blood vessel, such as a saphenous vein graft. However, some patients do not have appropriate vessels to use because of systemic disease or secondary surgery. On the other hand, there is no commercially available synthetic vascular graft available on the market for small diameter (<6 mm) blood vessels like coronary, carotid, and peripheral popliteal arteries. Tissue-engineered vascular grafts (TEVGs) are studied in recent decades as a promising alternative to synthetic arterial prostheses. Yet only a few studies have proceeded to a clinical trial. Recent studies have uncovered that the host immune response can be directed toward increasing the success of a TEVG by shedding light on ways to modulate the macrophage response and improve the tissue regeneration outcome. In this review, the basic concepts of vascular tissue engineering and immunoengineering are considered. The state-of-art of TEVGs is summarized and the role of macrophages in TEVG regeneration is analyzed. Current immunomodulatory strategies based on biomaterials are also discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.